NeurAxis Inc. Issues Letter to Shareholders
13. Januar 2025 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
08. Januar 2025 09:00 ET
|
NeurAxis, Inc.
Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or...
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
06. Januar 2025 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
10. Dezember 2024 09:00 ET
|
NeurAxis, Inc.
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software. NeurAxis Inc. will begin...
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
12. November 2024 08:10 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
05. November 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
04. November 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
22. Oktober 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
19. September 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
27. August 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...